DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin

Chemistry and Biology

Volumn 12, Issue 11, 2005, Pages 1201-1210

  David Cordonnier, Marie Hélène ^a   Gajate, Consuelo ^b,c   Olmea, Osvaldo ^d   Laine, William ^a   De La Iglesia Vicente, Janis ^b   Perez, Carlos ^d   Cuevas, Carmen ^d   Otero, Gabriel ^d   Manzanares, Ignacio ^d   Bailly, Christian ^a   Mollinedo, Faustino ^b  

^a INSERM   (France)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; DNA; ISOQUINOLINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TETRAHYDROISOQUINOLINE DERIVATIVE; TRABECTEDIN;

ARTICLE; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; DNA DENATURATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; TEMPERATURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE, TUMOR; DIOXOLES; DNA; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOQUINOLINES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR STRUCTURE; NUCLEIC ACID DENATURATION; SUBSTRATE SPECIFICITY; TEMPERATURE; TETRAHYDROISOQUINOLINES;

EID: 27744452788     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2005.08.009     Document Type: Article

References (26)

1. W.W. Li, N. Takahashi, S. Jhanwar, C. Cordon-Cardo, Y. Elisseyeff, J. Jimeno, G. Faircloth, and J.R. Bertino Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent Clin. Cancer Res. 7 2001 2908 2911
2. E. Erba, D. Bergamaschi, L. Bassano, G. Damia, S. Ronzoni, G.T. Faircloth, and M. D'Incalci Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action Eur. J. Cancer 37 2001 97 105
3. G.J. Aune, T. Furuta, and Y. Pommier Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action Anticancer Drugs 13 2002 545 555
4. K.W. Scotto ET-743: more than an innovative mechanism of action Anticancer Drugs 13 Suppl 1 2002 S3 S6
5. C. van Kesteren, M.M. de Vooght, L. Lopez-Lazaro, R.A. Mathot, J.H. Schellens, J.M. Jimeno, and J.H. Beijnen Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin Anticancer Drugs 14 2003 487 502
6. Y. Pommier, G. Kohlhagen, C. Bailly, M. Waring, A. Mazumder, and K.W. Kohn DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata Biochemistry 35 1996 13303 13309
7. F. Gago, and L.H. Hurley Devising a structural basis for the potent cytotoxic effects of ecteinascidin 743 M. Demeunynck C. Bailly W.D. Wilson Small Molecule DNA and RNA Binders Volume 2 2003 Wiley-VCH Weinheim, Germany 643 675
8. Y. Takebayashi, P. Pourquier, A. Yoshida, G. Kohlhagen, and Y. Pommier Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove Proc. Natl. Acad. Sci. USA 96 1999 7196 7201
9. M. Minuzzo, S. Marchini, M. Broggini, G. Faircloth, M. D'Incalci, and R. Mantovani Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743 Proc. Natl. Acad. Sci. USA 97 2000 6780 6784
10. M. Garcia-Rocha, M.D. Garcia-Gravalos, and J. Avila Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15 Br. J. Cancer 73 1996 875 883
11. C. van Kesteren, E. Cvitkovic, A. Taamma, L. Lopez-Lazaro, J.M. Jimeno, C. Guzman, R.A. Math t, J.H. Schellens, J.L. Misset, and E. Brain Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study Clin. Cancer Res. 6 2000 4725 4732
12. A. Taamma, J.L. Misset, M. Riofrio, C. Guzman, E. Brain, L. Lopez Lazaro, H. Rosing, J.M. Jimeno, and E. Cvitkovic Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors J. Clin. Oncol. 19 2001 1256 1265
13. D.P. Ryan, T. Puchalski, J.G. Supko, D. Harmon, R. Maki, R. Garcia-Carbonero, C. Kuhlman, J. Winkelman, P. Merriam, and T. Quigley A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors Oncologist 7 2002 531 538
14. G. Damia, S. Silvestri, L. Carrassa, L. Filiberti, G.T. Faircloth, G. Liberi, M. Foiani, and M. D'Incalci Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways Int. J. Cancer 92 2001 583 588
15. Y. Takebayashi, P. Pourquier, D.B. Zimonjic, K. Nakayama, S. Emmert, T. Ueda, Y. Urasaki, A. Kanzaki, S.I. Akiyama, and N. Popescu Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat. Med. 7 2001 961 966
16. C. Gajate, F. An, and F. Mollinedo Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis J. Biol. Chem. 277 2002 41580 41589
17. E.J. Corey, D.Y. Gin, and R.S. Kania Enantioselective total synthesis of ecteinascidin 743 J. Am. Chem. Soc. 118 1996 9202 9203
18. C. Cuevas, M. Perez, M.J. Martin, J.L. Chicharro, C. Fernandez-Rivas, M. Flores, A. Francesch, P. Gallego, M. Zarzuelo, and F. de La Calle Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B Org. Lett. 2 2000 2545 2548
19. E.J. Martinez, T. Owa, S.L. Schreiber, and E.J. Corey Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743 Proc. Natl. Acad. Sci. USA 96 1999 3496 3501
20. B.M. Moore, F.C. Seaman, R.T. Wheelhouse, and L.H. Hurley Mechanism of the catalytic activation of eceteinascidin 743 and its subsequent alkylation of guanine N2 J. Am. Chem. Soc. 120 1998 2490 2491
21. B.M. Moore, F.C. Seaman, and L.H. Hurley NMR-based model of an ecteinascidin 743-DNA adduct J. Am. Chem. Soc. 23 1997 5475 5476
22. F.C. Seaman, and L.H. Hurley Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding J. Am. Chem. Soc. 120 1998 13028 13041
23. A.T. Plowright, S.E. Schaus, and A.G. Myers Transcriptional response pathways in a yeast strain sensitive to saframycin a and a more potent analog: evidence for a common basis of activity Chem. Biol. 9 2002 607 618
24. C. Xing, J.R. LaPorte, J.K. Barbay, and A.G. Myers Identification of GAPDH as a protein target of the saframycin antiproliferative agents Proc. Natl. Acad. Sci. USA 101 2004 5862 5866
25. R. Menchaca, V. Martinez, A. Rodriguez, N. Rodriguez, M. Flores, P. Gallego, I. Manzanares, and C. Cuevas Synthesis of natural ecteinascidins (ET-729, ET-745, ET-759B, ET-736, ET-637, ET-594) from cyanosafracin B J. Org. Chem. 68 2003 8859 8866
26. C. Gajate, A.M. Santos-Beneit, A. Macho, M. Lazaro, A. Hernandez-De Rojas, M. Modolell, E. Munoz, and F. Mollinedo Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells Int. J. Cancer 86 2000 208 218